8AT Stock Chart & Stats
€3.36
-€0.01(-0.54%)
At close: 4:00 PM EST
€3.36
-€0.01(-0.54%)
Day’s Range― - ―
52-Week Range€1.28 - €4.94
Previous CloseN/A
Volume0.00
Average Volume (3M)880.00
Market Cap
€694.93M
Enterprise Value€379.61
Total Cash (Recent Filing)€105.42M
Total Debt (Recent Filing)€1.99M
Price to Earnings (P/E)―
Beta0.20
Next Earnings
Aug 12, 2026EPS Estimate
-0.14Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.56
Shares Outstanding139,663,680
10 Day Avg. Volume0
30 Day Avg. Volume880
Financial Highlights & Ratios
PEG Ratio0.08
Price to Book (P/B)3.58
Price to Sales (P/S)47.18
P/FCF Ratio-7.84
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€9.40Price Target Upside179.66% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
EPS Forecast (FY)-0.59
Revenue Forecast (FY)€5.00M
Bulls Say, Bears Say
Bulls Say
Low Leverage / Balance Sheet FlexibilityVery low debt reduces financing-related fixed costs and preserves optionality for funding R&D and trials. With minimal interest burden the company retains flexibility to pursue partnerships, milestone payments or equity raises without immediate solvency pressure, supporting clinical programs over the next 2–6 months.
Strong Recent Gross MarginsConsistently high gross margins indicate favorable unit economics at the product or platform level. If clinical assets advance to commercial stages, these margins provide a structural advantage for profitability leverage and pricing flexibility, improving long-term viability as revenue scales.
Positive Phase 1a Data And Clarified Pipeline FocusPositive first-in-human results for ATI-052 materially de-risk that bispecific program and support a best-in-class pharmacokinetic profile (quarterly dosing potential). Selecting lichen planus as a lead indication clarifies development priorities and could target a meaningful unmet-market opportunity, strengthening long-term commercial prospects.
Bears Say
Persistent Cash BurnSustained negative operating and free cash flow requires ongoing external capital to fund operations and trials. That dependency shortens effective runway, forces management to allocate time to financing, and raises execution risk if funding conditions deteriorate, constraining long-term R&D plans.
Small, Volatile Revenue And Deep Operating LossesA tiny and inconsistent revenue base cannot absorb fixed R&D and SG&A costs, leaving operating losses large relative to sales. Without sustainable revenue growth, the company cannot self-fund development or scale commercialization, prolonging reliance on external financing and increasing business risk.
Financing-driven Dilution RiskFrequent or material equity financings to cover cash burn dilute existing shareholders and can shift management focus toward near-term capital raises rather than long-term value creation. This structural funding model raises investor risk and can reduce per-share upside if clinical timelines slip.
Aclaris Therapeutics News
8AT FAQ
What was Aclaris Therapeutics’s price range in the past 12 months?
Aclaris Therapeutics lowest stock price was €1.28 and its highest was €4.94 in the past 12 months.
What is Aclaris Therapeutics’s market cap?
Aclaris Therapeutics’s market cap is €694.93M.
When is Aclaris Therapeutics’s upcoming earnings report date?
Aclaris Therapeutics’s upcoming earnings report date is Aug 12, 2026 which is in 22 days.
How were Aclaris Therapeutics’s earnings last quarter?
Aclaris Therapeutics released its earnings results on May 12, 2026. The company reported -€0.131 earnings per share for the quarter, beating the consensus estimate of -€0.138 by €0.007.
Is Aclaris Therapeutics overvalued?
According to Wall Street analysts Aclaris Therapeutics’s price is currently Undervalued.
Does Aclaris Therapeutics pay dividends?
Aclaris Therapeutics does not currently pay dividends.
What is Aclaris Therapeutics’s EPS estimate?
Aclaris Therapeutics’s EPS estimate is -0.14.
How many shares outstanding does Aclaris Therapeutics have?
Aclaris Therapeutics has 139,663,680 shares outstanding.
What happened to Aclaris Therapeutics’s price movement after its last earnings report?
Aclaris Therapeutics reported an EPS of -€0.131 in its last earnings report, beating expectations of -€0.138. Following the earnings report the stock price went up 0.434%.
Which hedge fund is a major shareholder of Aclaris Therapeutics?
Currently, no hedge funds are holding shares in DE:8AT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Aclaris Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€9.40 (179.66% Upside)
€9.40 (179.66% Upside)
Insider Transactions
Sold Shares
Worth €1.2M over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-27.63%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
0.32%
Trailing 12-Months
Company Description
Aclaris Therapeutics
Aclaris Therapeutics, Inc., a biopharmaceutical firm operating in the United States, is currently in the clinical development phase, focused on creating novel therapeutic agents for various immune-inflammatory conditions. The company's operations are divided into two primary divisions: the Therapeutics segment, dedicated to discovering and progressing innovative treatments to address crucial unmet needs in immuno-inflammatory disorders; and the Contract Research segment, which delivers specialized laboratory services. The company's pipeline features several investigational compounds. Among these is Zunsemetinib, an MK2 inhibitor, being developed to treat moderate to severe cases of rheumatoid arthritis, psoriatic arthritis, and hidradenitis suppurativa. Another significant candidate is ATI-1777, a soft JAK 1/3 inhibitor, intended for the management of moderate to severe atopic dermatitis. Additionally, Aclaris is advancing ATI-2138, an ITK/TXK/JAK3 inhibitor, as a potential intervention for T cell-mediated autoimmune diseases; a Gut-Biased Program targeting inflammatory bowel disease; and ATI-2231, an MK2 inhibitor, for the treatment of pancreatic and metastatic breast cancer. Established in 2012, Aclaris Therapeutics, Inc. has its corporate headquarters situated in Wayne, Pennsylvania.
8AT Stock 12 Month Forecast
Average Price Target
€9.40
▲(179.66% Upside)